Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Launched by DR. ALBERT KAR-KIN CHUNG · Jul 18, 2023

Keywords

ClinConnect Summary

This clinical trial, called the ReSD-HK study, is looking at how well the medication brexpiprazole (also known as Rexulti) works for people with schizophrenia and depression in everyday settings. Brexpiprazole is a type of medication called a second-generation antipsychotic, which is often used to help manage symptoms of psychosis and depression. The researchers want to understand how effective this medication is and how well patients tolerate it when they take it in real life, rather than just in a controlled clinical environment.

To participate in this trial, individuals must be between 18 and 65 years old, able to read and understand English or Chinese, and must have a diagnosis of a psychotic disorder or depression. Participants should also be currently taking brexpiprazole for less than four weeks at the time they join the study. Those who are interested can expect regular check-ins to monitor their progress and any side effects from the medication. This study is important because it aims to provide valuable information on how brexpiprazole can help manage these mental health conditions in a real-world context.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18- 65 years old at the time of enrollment
• • Able to read and communicate in English and/or Chinese
• • Able to give informed consent
• • Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33)
• • is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment
• Exclusion Criteria:
• • Age \<18 years old
• • Unable to read English or Chinese
• • Unable to give informed consent
• • Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)